Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database
| Autor: | Parikh, Kaushal, Dimou, Anastasios, Leventakos, Konstantinos, Mansfield, Aaron S., Shanshal, Mohamed, Wan, Yin, Lin, Huamao M., Vincent, Sylvie, Elliott, Jennifer, Bonta, Ioana R. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology November 2024 19(11):1539-1549 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|